As a drug development company we concentrate on combining the targeting properties of antibodies with the effectiveness of an ultra-potent toxin with antibody-drug conjugates (ADC), that are more effective against cancer.
Key USP of our technology is the potential to treat multi-resistant tumors and "dormant or quiescent" tumor cells, which are regarded as a main reason for metastasis and resistance.
...
...
As a preclinical CRO we offer explorative pharmacology, drug metabolism and pharmacokinetics (DMPK) analysis and molecular biology.
Our core competence is the preclinical profiling of small molecules or biologicals destined for the treatment of cancer or inflammatory/autoimmune diseases.
